Emerging evidence indicates that Sodium–Glucose Co-transporter 2 (SGLT2) inhibitors may enhance pancreatic β-cell function and improve insulin resistance in individuals with type 2 diabetes, suggesting that certain antidiabetic therapies could play a direct role in preserving endogenous insulin production, which has been linked to improved HRQoL [44]. Here, SLC5A2 is linked to Insulin resistance.